MPGN II--genetically determined by defective complement regulation?

Area of Science:

• Nephrology
• Immunology
• Genetics

Background:

• Membranoproliferative glomerulonephritis type II (MPGN II) is a rare kidney disease characterized by complement deposits in the glomerular basement membrane (GBM).
• MPGN II leads to progressive renal dysfunction and end-stage renal disease due to GBM functional impairment.
• Pathogenesis involves complement dysregulation, including C3 nephritic factor (C3NeF) and other genetically determined factors affecting complement control.

Discussion:

• Defective complement regulation in MPGN II can arise from various genetic factors beyond C3NeF.
• Factor H deficiency, identified in animal models and patients, represents a significant cause of complement system activation in MPGN II.
• Mutations in the Factor H gene, autoantibodies against Factor H or C3, and C3 mutations contribute to impaired complement regulation.

Key Insights:

• MPGN II pathogenesis is linked to a dysregulated complement system, not solely C3NeF.
• Factor H deficiency is a key factor in MPGN II, leading to uncontrolled complement activation.
• Multiple genetic and autoimmune factors can disrupt complement regulation in MPGN II.

Outlook:

• Identifying specific complement defects in MPGN II patients is crucial for targeted therapies.
• Plasma infusion may serve as a treatment to replace missing complement factors, potentially halting or slowing disease progression.
• Further research into the genetic and autoimmune underpinnings of MPGN II can reveal novel therapeutic targets.